Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan

Sagami, Shintaro; Nishikawa, Kiyohiro; Yamada, Fumika; Suzuki, Yasuo; Watanabe, Mamoru; Hibi∥, Toshifumi

doi:10.1111/jgh.15399

Public

Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan

Published in Journal of Gastroenterology and Hepatology • Jan 16, 2021

Authors:

Shintaro Sagami

Kiyohiro Nishikawa

Fumika Yamada

Abstract

BACKGROUND AND AIM: CT-P13, an infliximab (IFX) biosimilar, was approved for treatment of inflammatory bowel disease. However, no comparison with the originator IFX in this indication has been conducted in Japan where endemic levels of tuberculosis and hepatitis virus infection are not low. We evalu...

Subject

Medicine

Infliximab

Biosimilar

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!